00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
20:32 , Jan 13, 2017 |  BC Week In Review  |  Clinical News

Cefiderocol: Ph II APEKs-cUTI data

Top-line data from 371 hospitalized adult patients with Gram-negative cUTI with or without pyelonephritis in the microbiological intent-to-treat (mITT) population of the double-blind, international Phase II APEKs-cUTI trial showed that 2 g IV cefiderocol every...
00:16 , Jan 13, 2017 |  BC Extra  |  Clinical News

Shionogi's cefiderocol passes Phase II cUTI test

Shionogi & Co. Ltd. (Tokyo:4507) said cefiderocol (S-649266) met FDA's pre-specified primary endpoint of the Phase II APEKs-cUTI study to treat complicated urinary tract infection with Gram-negative bacteria. The company said it plans to submit...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

Shionogi, GlaxoSmithKline deal

Shionogi and GlaxoSmithKline terminated a 2010 deal to jointly develop and commercialize cephem antibiotics against Gram-negative bacteria. The two products generated under the deal, Shionogi’s S-649266 and GSK’s GSK3342830, will be developed by...